PF-Atlas › Clinical Trials › NCT05349760
A Phase 2 Study to Evaluate Safety and Efficacy of AMB-05X in Subjects With Idiopathic Pulmonary Fibrosis
AMB-05X · Phase 2
Registry ID
NCT05349760
Phase
Phase 2
Status
Withdrawn
Drug / intervention
AMB-05X
Sponsor
AmMax Bio, Inc.
Start
2023-03
About this trial
AMB-053-01 is a randomized, placebo controlled, multicenter study which will enroll approximately 36 subjects ages 40 and older with IPF for 6 doses over a 24-week dosing period.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT05349760 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.